Configurable Study Design

Your EDC solution should work the way you work.  It should mirror your organization’s workflow, while accommodating the unique requirements of different studies of all sizes, phases and therapeutic areas.  User configurability is an important first step to ensuring that your EDC solution works for you – letting you focus on clinical research rather than software programming.

With a browser configurable interface, ClinicalAnalytics 4.0 can be deployed faster than any other EDC platform.  Users can design and manage all aspects of their studies through easy-to-use wizards and templates, accelerating the deployment of their trials.  Flexible permission-based controls and real-time data access ensure that authorized users can review their data and meta data whenever they want. This flexibility allows customers to add new information to their trial, or even change its design after protocol amendments.

Configurability also extends across different functional areas. Collaborative discussion forums, for example, allow users to create groups and subgroups and control read/access/edit permissions separately to better manage communication and sensitive information exchange, such as adverse events or medical images, among researchers.  In addition, data managers can configure specific workflows, procedures and processes to more efficiently manage their trial and the accuracy of its data.

Configurable Study Design Features:

Comprehensive Study Editor configures every aspect of your data capture and management needs, including eCFRs, reports and document templates.  In addition, this features offers:

  • Form-based validation rules
  • Multilanguage support
  • Configurable visit structures
  • Integrated randomization capabilities

Form Reuse streamlines and simplifies the management of standard and customer-created form libraries, enables users to re-use existing eCRFs to speed study start times.

Web-based Randomization enables real-time blinding of study participants through a secure browser interface, eliminating the need for costly IVRs systems while supporting adaptive clinical trial designs.

.